FY4/22
Supplementary Materials

June 3, 2022

１．Consolidated Results■Year-on-Year(¥ million)

FY4/21
results

FY4/22
results

YoYchange

YoYchange(%)

Net sales

297,305

316,247+18,942+6.4

Gross profit

46,15549,971+3,816+8.3

35,222

34,832(390)(1.1)

10,932

15,139+4,207+38.5

12,64916,041+3,392+26.8

Profit attributableto owners of parent

6,697

7,092+395+5.9

Earnings pershare(¥)

189.04201.47+12.43+6.6% of net sales

SG&A expenses% of net sales

Operating profit% of net salesOrdinary profit% of net sales

15.5

15.8

11.8

11.0

3.7

4.8

4.3

5.1

2.2

2.3

% of net sales

Figures in the table are rounded down

■Vs Plan(¥ million)

FY4/22plan

FY4/22
results

Vs planchangeVs planchange(%)

Net sales

315,000

316,247+1,247+0.4

Gross profit

51,60049,971(1,629)(3.2)

36,60034,832(1,768)(4.8)

15,00015,139+139+0.9

15,50016,041+541+3.5

Profit attributableto owners of parent

8,300

7,092(1,208)(14.6)

Earnings pershare(¥)

234.28201.47(32.81)(14.0)% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales

16.4

15.8

11.6

11.0

4.8

4.8

4.9

5.1

2.6

% of net sales

Figures in the table are rounded down

2.2-1-２. Segment Information（Dispensing Pharmacy Business）■Year-on-Year(¥ million)

FY4/21
results

FY4/22
results

YoYchange

YoYchange(%)

Net sales

263,095

283,111+20,016+7.6

Gross profit

33,16038,194+5,034+15.2

SG&A expenses

13,99813,875(123)(0.9)

Operating profit

19,162

24,319+5,157+26.9

25,082+4,135+19.7% of net sales% of net sales% of net sales

Segment income% of net sales

12.6

13.5

5.3

4.9

7.3

8.6

20,9478.0

8.9

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the consolidated statement of income■Vs Plan(¥ million)

FY4/22plan

FY4/22
results

Vs planchangeVs planchange(%)

Net sales

276,300

283,111+6,811+2.5

Gross profit

36,90038,194+1,294+3.5

SG&A expenses

14,60013,875(725)(5.0)

Operating profit

22,30024,319+2,019+9.1

22,70025,082+2,382+10.5% of net sales% of net sales% of net sales

Segment income% of net sales

13.4

13.5

5.3

4.9

8.1

8.6

8.2

8.9

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the consolidated statement of income-2-3. Segment Information（Cosmetic and Drug Store Business）■Year-on-Year(¥ million)

FY4/21
results

FY4/22
results

YoYchangeNet sales

19,41920,558+1,139Gross profit

7,216

7,030(186)% of net sales

37.2

34.2

YoYchange(%)+5.9(2.6)

SG&A expenses

9,358

8,858(500)

Operating profit(2,141)(1,827)+314-

Segment income(1,999)(1,764)+235-% of net sales% of net sales% of net sales

48.2

43.1

-

(5.3)

---

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the consolidated statement of income■Vs Plan(¥ million)

FY4/22plan

FY4/22
results

Vs planchange

Vs planchange(%)

Net sales

25,00020,558(4,442)(17.8)

Gross profit

9,200

7,030

(2,170)(23.6)

9,900

8,858

(1,042)(10.5)

Operating profit(700)(1,827)(1,127)-Segment income(670)(1,764)(1,094)-% of net sales

SG&A expenses% of net sales% of net sales% of net sales

36.8

34.2

43.1

39.6

---

-

Figures in the table are rounded down
Segment income is adjusted to ordinary profit shown on the consolidated statement of income-3-

4. Sales Verification■Dispensing Pharmacy Business (YoY）■Dispensing Pharmacy Business（Vs Plan）

Net sales

Net sales（%）

Average
Prescription
prescription
volume（%）
price

Average
Prescription
prescription
volumeprice

Same store (1,021)+3.1+1.9+1.1

Same store (1,021)+4.4(0.8)+5.2Store openings in theprevious year (29)+124.0+147.4(9.4)

Store openings in theprevious year (29)

(3.3)

(5.7)

+2.5

+7.4

+5.3

+2.0

Total (1,099)+2.3(3.0)+5.6

Total (1,099)■Cosmetic and Drug Store Business（YoY）■Cosmetic and Drug Store Business (Vs Plan）

Net sales

Net sales（%）
Same store (55)Store openings in theprevious year (10)Total (78)

Average
Number ofspending per
customers
customer（%）

Average
Number ofspending per
customers
customer

(1.3)

+6.4

(7.3)

Same store (55)(15.3)(14.0)(1.5)+114.9+132.8(7.7)

Store openings in theprevious year (10)(21.8)(17.8)

(4.9)

+5.9

+14.9

(7.8)

Total (78)(17.8)(16.0)(2.1)

Changed accounting policies for revenue recognition from FY4/22（Reference）■Cosmetic and Drug Store Business（YoY）（%）
Same store (55)Store openings in theprevious year (10)Total (78)

Net salesAverage
Number ofspending per
customers
customer■Cosmetic and Drug Store Business (Vs Plan）（%）

Net sales

Average
Number ofspending per
customers
customer

+4.1

+6.4

(2.2)

Same store (55)

(14.4)(14.0)(0.4)+125.3+132.8(3.2)

Store openings in theprevious year (10)(20.3)(17.8)

(3.1)

+11.5

+14.9

(2.9)

Total (78)(16.7)(16.0)(0.9)

For comparison purposes, FY4/22 figures are calculated to adjust to the results before the changes in accounting
policies for revenue recognition-4-5. Consolidated Balance Sheet■Assets(¥ million)
Cash on hand and in banks
Notes and accounts receivable
Inventories
Total current assets
Buildings and structures,net
Land
Lease assets
Total property,plant andequipment
Goodwill
Lease assets
Total intangible fixed assets
Investments in securities
Deferred tax assets
Deposits and guarantees
Total investments and otherassets
Total fixed assets
Total deferred assets
Total assets

End-FY4/20

End-FY4/21

End-FY4/22

Change46,321
13,653
15,32287,802
16,60910,960272

55,271
13,475
14,28596,398
16,270
10,39010059,729
10,11014,790100,765
17,5128,581
28+4,458(3,365)+505+4,367+1,242(1,809)(72)

30,87430,22930,636+407

42,123
5
44,916
2,295
4,211
19,14439,057
1
42,666
2,697
4,415
20,31936,352
041,2192,503
5,319
22,785(2,705)(1)(1,447)(194)+904+2,466

29,84134,36839,840+5,472

105,632
15
193,451

107,264
203,662

111,696
212,461+4,432+8,799Figures in the table are rounded down

Change:End-FY4/22 compared with end-FY4/21
Capital expenditures(Purchases of property, plant and equipment and intangible fixed assets + Deposits and guarantees)
totaled ¥12,756million■Liabilities and Net Assets(¥ million)

End-FY4/20

End-FY4/21

End-FY4/22

Total liabilities and net assets

47,1873,642
193
74,700
2,432
154
7,747
82,447
21,89420,50068,758111,151
111,003
193,451

Figures in the table are rounded down

Change:End-FY4/22 compared with end-FY4/21

Accounts payable
Short-term debt
Lease obligations
Total current liabilities
Long-term debt
Lease obligations
Total long-term liabilities
Total liabilities
Common stock
Capital surplus
Retained earnings
Total shareholders’ equity
Total net assets

46,7583,670
94
74,1608,297
3713,66487,82521,89420,50073,506
115,899
115,837
203,662-5-50,7562,643
2281,8055,815
911,64593,45021,89420,50078,661
119,038
119,010
212,461

Change+3,998(1,027)(72)+7,645(2,482)(28)(2,019)+5,625+5,155+3,139+3,173+8,799

6. FY4/23 Plan (Consolidated)(¥ million)
Net sales

297,305

316,247

363,000+46,753+14.8

Gross profit

46,15549,97158,720+8,749+17.5

35,222

34,832

38,720+3,888+11.2

10,932

15,13920,000+4,861+32.1

12,64916,041

20,500+4,459+27.8

Profit attributableto owners of parent

6,697

7,092

11,000+3,908+55.1

Earnings pershare(¥)

189.04201.47313.15+111.68+55.4

Annual dividend (¥)

55.00

55.00

60.00

+5.00

+9.1

% of net sales

SG&A expenses% of net sales

Operating profit% of net sales

Ordinary profit% of net sales% of net sales

15.5

11.8

3.7

4.32.3FY4/22results

YoYchange

FY4/21results

15.8

11.0

4.8

5.1

2.2

Figures in the table are rounded down
Change:FY4/23 plan compared with FY4/22 results-6-

FY4/23
plan

16.2

10.7

5.5

5.6

3.0

YoYchange (%)

7. Transition of Store Openings■Number of Store Openings in Dispensing Pharmacy Business
FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22
Organic

3640322725

23141525

M&A26119110182

1113461424Total

616754881

1,066

1,029

1,132

1,0881,0651,099■Number of Store Openings in Cosmetic and Drug Store Business
FY4/14 FY4/15 FY4/16 FY4/17 FY4/18 FY4/19 FY4/20 FY4/21 FY4/22Organic335947151112Total

5956

5252485463

6978

Inquiries related to this presentation should be addressed toAIN HOLDINGS INC.
Corporate Planning Division
TEL(81)11-814-0010
FAX(81)11-814-5550
https://www.ainj.co.jp/
This document may not be reproduced or distributed to any third party without
prior approval of AIN HOLDINGS INC. This document has been prepared forinformation purpose only and does not form part of a solicitation to sell orpurchase any securities. Information contained herein may be changed orrevised without prior notice. This document may contain forecasting statements
as to future results of operations. No forecast statement can be guaranteed andactual results of operations may differ from those projected.

-7-